Fennec Pharmaceuticals Inc.
NASDAQ:FENCBiotechnology
-$0.12 today
- Market cap
- $470.62M
- Beta
- 1.08
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$0.24
Volume 0.59M
Average 0.26M
FENC Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Fennec Pharmaceuticals Inc.NASDAQ: FENC
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $201K, compared with -$1.17M a year earlier. Trailing-twelve-month net income was -$8.38M. Over 3 fiscal years it compounded at -24.3% a year.
Context
- Net income amounted to 23.0% of revenue in FY2025, up 22.1 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of $9M (+187.6%) for the fiscal year ending Dec 2026, a slowdown from the +2256.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $201K+104.2% QoQ
- Last fiscal yearDec 2025
- -$10.27M+2256.6% YoY
- LTMMar 2026
- -$8.38M-42.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +117.3% | +124.2% | +6.9 pp |
| 1 year | +2256.6% | +187.6% | -2069.0 pp |
| 3-year CAGR | -24.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (10.27M) USD
- Year-over-year change
- -2256.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.27M) | -2256.6% |
| FY2024 | 2024-12-31 | (436K) | +97.3% |
| FY2023 | 2023-12-31 | (16.05M) | +32.3% |
| FY2022 | 2022-12-31 | (23.71M) | -36.7% |
| FY2021 | 2021-12-31 | (17.35M) | — |
Net Income vs competitors
How FENC compares with its peers on the latest reported figures
- FENC's LTM Mar 2026 net income of $8.38M is the smallest of the 11 companies compared; the peer median is $65.93M.
- Its year-over-year change of -42.0% is the 9th highest of 11, against a peer median of -17.2%.
- Net income amounts to 16.4% of revenue for FENC, versus a peer median of 827.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.77M | +296.2% | — | 8550.6% | |
| LTM Mar 2026 | $133.22M | -9.9% | +14.2% | 1189.1% | |
| LTM Mar 2026 | $84.74M | -216.1% | +23.4% | 143627.1% | |
| LTM Mar 2026 | $77.8M | -39.1% | -4.8% | 465.3% | |
| LTM Mar 2026 | $69.87M | +152.1% | +61.9% | — | |
| LTM Mar 2026 | $61.98M | -35.7% | -12.4% | 89.6% | |
| LTM Mar 2026 | $57.09M | -16.9% | +0.6% | — | |
| LTM Mar 2026 | $54.64M | -17.6% | +16.2% | 167.0% | |
| LTM Mar 2026 | $43.21M | -948.8% | — | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $42.72M | +84.6% | +27.3% | — |
| LTM Mar 2026 | $8.38M | -42.0% | -24.3% | 16.4% | |
| Peer median (excluding FENC) | $65.93M | -17.2% | +15.2% | 827.2% | |
Competitors are the stored peer set for FENC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (10.27M) |
| Depreciation & Amortization | 16K | 149K | 287K | 959K | 103K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.01M | 4.22M | 5.35M | 5.06M | 7.03M |
| Change in Working Capital | (138K) | (509K) | (8.17M) | (7.33M) | (15.09M) |
| Accounts Receivables | 0 | (1.55M) | (7.27M) | (7.87M) | (12.66M) |
| Inventory | 0 | (576K) | (1.58M) | 579K | (1.3M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 1.42M |
| Other Working Capital | (138K) | 1.61M | 683K | (35K) | (2.55M) |
| Other Non-Cash Items | (769K) | 1.8M | 1.43M | 28.73M | 5.76M |
| Operating Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (12.47M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 5M | 20.17M | 5M | (13M) | (19.82M) |
| Common Stock Issued | 33K | 0 | 0 | 0 | 45.01M |
| Common Stock Repurchased | 0 | (194K) | (78K) | (176K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (55K) | 753K | 1.72M | (439K) | (2.57M) |
| Financing Cash Flow | 4.98M | 20.73M | 6.64M | (13.62M) | 22.63M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (9.24M) | 2.67M | (10.51M) | 13.37M | 10.15M |
| Free Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (12.47M) |
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
Intrinsic Alpha fair value
Locked
Current Price
$13.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.